Abstract
The cancer genome-profiling test is performed to analyze exome gene mutations, amplifications, deletions, fusion gene expression, etc. in tumor tissues with a next-generation sequencer to identify tumor-specific driver genes. The cancer genome-profiling test is covered by medical insurance for patients with malignant brain tumors in Japan, but it is limited to patients with good PS(performance status), considering the conditions for participation in clinical trials. The findings of the expert panel will create more opportunities to administer new therapeutic agents for clinical trials for malignant brain tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
